Share chart Neurocrine Biosciences
Extended chart
Simple chart
About Neurocrine Biosciences
Neurocrine Biosciences является публичной биофармацевтической компанией, основанной в 1992 году. Головной офис компании находится в Сан-Диего, штат Калифорния, и возглавляет генеральный директор Кевин Горман. Нейрокрин разрабатывает методы лечения неврологических и эндокринных заболеваний и расстройств.Main settings
IPO date
1996-05-23
ISIN
US64125C1099
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Underestimation
Title | Value | Grade |
P/S | 6.03 | 1 |
P/BV | 5.49 | 2 |
P/E | 41.64 | 4 |
Efficiency
Title | Value | Grade |
ROA | 9.79 | 3 |
ROE | 14.16 | 4 |
ROIC | 5.01 | 2 |
Dividends
Title | Value | Grade |
Dividend yield | 0 | 0 |
DSI | 0 | 0 |
Average dividend growth | 0 | 0 |
Debt
Title | Value | Grade |
Debt/EBITDA | 0.7114 | 9 |
Debt/Ratio | 0.1224 | 10 |
Debt/Equity | 0.436 | 10 |
Growth impulse
Title | Value | Grade |
Yield Revenue, % | 124.31 | 10 |
Yield Ebitda, % | 95.33 | 9 |
Yield EPS, % | -20.88 | 0 |
Prices
Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
Yesterday | 125.01 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
Week | 125.39 $ | 0 $ | 0 $ | -0.3031 % | 0 % | 0 % |
Month | 119.12 $ | 0 $ | 0 $ | +4.94 % | 0 % | 0 % |
Three month | 95.28 $ | 100.68 $ | 125.73 $ | +31.2 % | 0 % | 0 % |
Half a year | 152.42 $ | 87.54 $ | 153.29 $ | -17.98 % | 0 % | 0 % |
Year | 152.55 $ | 87.54 $ | 153.29 $ | -18.05 % | 0 % | 0 % |
3 years | 102.87 $ | 87.54 $ | 153.29 $ | +21.52 % | 0 % | 0 % |
5 years | 107.91 $ | 73.55 $ | 153.29 $ | +15.85 % | 0 % | 0 % |
10 years | 42.65 $ | 32.19 $ | 153.29 $ | +193.11 % | 0 % | 0 % |
Year to date | 146.76 $ | 87.54 $ | 153.29 $ | -14.82 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
PSYK ETF | 4.51 | 0 | 0.75 |
VictoryShares Nasdaq Next 50 ETF | 1.2271 | 4.94 | 0.18 |
Future Tech ETF | 1.15959 | 479.5 | 0.35 |
Principal Healthcare Innovators ETF | 1.15959 | -3.92 | 0.35 |
GraniteShares XOUT U.S. Large Cap ETF | 0.80826 | -24.16 | 0.60 |
First Trust Mid Cap US Equity Select ETF | 0.787 | -4.33 | 0.60 |
Donoghue Forlines Innovation ETF | 0.55247 | 20.73 | 0.69 |
Syntax Stratified MidCap ETF | 0.36602 | -0.3413 | 0.35 |
FCF US Quality ETF | 0.29911 | 9.04 | 0.59 |
iShares Morningstar Mid-Cap Growth ETF | 0.22135 | 450.65 | 0.06 |
iShares Morningstar Mid-Cap ETF | 0.1109 | 245.03 | 0.04 |
iShares Morningstar Large-Cap Growth ETF | 0.04883 | 245.22 | 0.04 |
iShares Factors US Growth Style ETF | 0.03532 | -6.31 | 0.25 |
Columbia U.S. ESG Equity Income ETF | 0.02679 | -4.51 | 0.35 |
iShares Morningstar Large-Cap ETF | 0.02418 | 186.3 | 0.03 |
0.76 | 106.52 | 0.35 |
---|
Similar companies
P/E & P/BV
Company management
Head | Job title | Payment | Year of birth |
Mr. Matthew C. Abernethy | Chief Financial Officer | 1.04M | 1980 (45 years) |
Mr. Eric S. Benevich | Chief Commercial Officer | 805k | 1965 (60 years) |
Jane Sorensen | Head of Investor Relations | N/A | |
Ms. Julie S. Cooke | Chief Human Resources Officer | N/A | 1966 (59 years) |
Dr. Kevin C. Gorman Ph.D. | CEO & Director | 1.9M | 1958 (67 years) |
Dr. Jude Onyia Ph.D. | Chief Scientific Officer | 621.66k | 1964 (61 year) |
Dr. Eiry Wyn Roberts M.D. | Chief Medical Officer | 1.04M | 1964 (61 year) |
Mr. Darin M. Lippoldt Esq. | Chief Legal Officer & Corporate Secretary | 921.01k | 1966 (59 years) |
Mr. Kyle W. Gano Ph.D. | Chief Business Development & Strategy Officer | 921.52k | 1973 (52 years) |
Mr. David Warren Boyer | Chief Corporate Affairs Officer | N/A | 1980 (45 years) |
About company
Address: United States, San Diego, 12780 El Camino Real - Open in google maps, Open in yandex maps
Website: http://www.neurocrine.com
Website: http://www.neurocrine.com